Adagio Medical Holdings (ADGM) AI Stock Analysis

• Market Cap: $29.38M
• Dividend Yield: N/A
• Average Volume (3M): 566.94K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.23
• Revenue Growth: 15.00%
• EPS Growth: 71.57%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.35
• Shares Outstanding: 15,381,565
• 10 Day Avg. Volume: 1,612,181
• 30 Day Avg. Volume: 566,936
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 704.17
• Enterprise Value/Gross Profit: -20.78
• Enterprise Value/Ebitda: -0.41
• 1Y Price Target: $2.00
• Price Target Upside: -1.48% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $2.00 ▼(-1.48% Downside)

Adagio Medical Holdings faces significant financial challenges, with consistent losses and negative cash flows being the most impactful factors. While technical indicators suggest some positive momentum, the company's negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events limits additional insights.

Adagio Medical Holdings Business Overview & Revenue Model

Company Description

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.

How the Company Makes Money

Adagio Medical Holdings generates revenue primarily through the sale of its medical devices and diagnostic tools to hospitals, clinics, and healthcare providers. The company implements a direct sales model complemented by distribution partnerships that expand its market reach. Additionally, ADGM may generate income through licensing agreements for its proprietary technologies, as well as through collaborations with research institutions and pharmaceutical companies that seek to integrate its innovations into their therapeutic offerings. These revenue streams are bolstered by ongoing investments in R&D that align with industry trends and regulatory approvals.

Adagio Medical Holdings Financial Statement Overview

Summary

Adagio Medical Holdings is facing significant financial challenges, with consistent losses and negative cash flows. Despite slight improvements in equity and cash position, the company remains highly leveraged and struggles with profitability.

Income Statement

Adagio Medical Holdings has experienced declining revenues over the past years, with a negative revenue growth rate from 2023 to 2024. The company has consistently reported negative gross profit and net income, indicating significant challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage, although it has improved from 2023 to 2024 as equity turned positive. The equity ratio remains low, suggesting limited financial stability. Despite improvements in stockholders' equity, the company still faces potential risks due to its high liabilities relative to assets.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, which have slightly improved from 2023 to 2024. The company has relied on financing activities to support its cash position, which may not be sustainable in the long term. The operating cash flow to net income ratio is negative, indicating cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	42.00K	269.00K	300.00K	189.00K	270.00K
Gross Profit	-1.42M	-1.67M	-1.01M	-686.00K	-888.00K
EBITDA	-72.02M	-62.48M	-27.41M	-23.42M	-19.60M
Net Income	-60.86M	-53.76M	-38.15M	1.07M	-6.56M
Balance Sheet
Total Assets	35.88M	48.45M	6.83M	151.78M	150.42M
Cash, Cash Equivalents and Short-Term Investments	8.20M	20.59M	1.38M	91.05K	501.24K
Total Debt	17.78M	16.27M	39.95M	120.00K	0.00
Total Liabilities	27.21M	28.54M	48.94M	8.89M	11.22M
Stockholders Equity	8.67M	19.91M	-42.11M	142.89M	139.20M
Cash Flow
Free Cash Flow	-20.78M	-16.36M	-25.99M	-987.19K	-2.34M
Operating Cash Flow	-27.51M	-15.99M	-25.65M	-485.19K	-19.31M
Investing Cash Flow	-954.00K	-1.65M	-340.00K	-500.00K	-1.27M
Financing Cash Flow	990.00K	15.63M	21.88M	75.00K	151.07M

Adagio Medical Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADGM, the sentiment is Positive. The current price of 2.03 is above the 20-day moving average (MA) of 1.70, above the 50-day MA of 1.53, and above the 200-day MA of 1.28, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 58.73 is Neutral, neither overbought nor oversold. The STOCH value of 78.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADGM.

Adagio Medical Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NMTC	58 Neutral	45.95M	-5.82	-65.26%	―	145.48%	67.36%
ADGM	45 Neutral	$29.38M	―	-329.16%	―	15.00%	71.57%
MDAI	45 Neutral	56.00M	-3.00	―	―	22.27%	49.22%
RBOT	39 Underperform	32.50M	-0.54	―	―	―	6.48%
COCH	38 Underperform	18.56M	-0.58	71.22%	―	-26.49%	-91.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Adagio Medical Holdings Corporate Events

Adagio Medical Holdings Appoints New CFO Deborah Kaster

On September 5, 2025, Adagio Medical Holdings appointed Deborah Kaster as Chief Financial Officer, expanding her role from Chief Business Officer. Kaster, who joined Adagio in March 2025, brings over 25 years of financial leadership experience and will oversee both business and financial operations. This strategic move aims to align Adagio’s financial and strategic priorities, enhancing its growth potential in the medical device industry.

The most recent analyst rating on (ADGM) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.

Adagio Medical Reports Q2 Financial Results Progress

On August 13, 2025, Adagio Medical Holdings announced its second quarter financial results, highlighting significant progress in its clinical studies and operational efficiency. The company reported a reduction in cash burn due to prioritization initiatives and continued strong enrollment in the FULCRUM-VT study, which is crucial for its market positioning in the treatment of ventricular tachycardia. Financially, Adagio reduced its net loss compared to the previous year, reflecting improved cost management and strategic focus.